文献速递其他结缔组织病

血清半乳凝素-9水平作为皮肌炎高恶性肿瘤风险的潜在生物标志物

Serum level of galectin-9 as a potential biomarker for high risk of malignancy in dermatomyositis.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

本研究检测了皮肌炎患者血清半乳凝素-9水平,发现其显著高于健康对照,且与新发未治疗肿瘤的皮肌炎患者相比稳定治疗肿瘤、非肿瘤相关皮肌炎及无皮肌炎肿瘤患者均更高;抗肿瘤治疗后显著下降。半乳凝素-9联合抗TIF1-γ抗体对皮肌炎合并肿瘤具有最高预测价值。

要点

  • 皮肌炎患者血清半乳凝素-9水平显著高于健康对照,且与CDASI-A评分正相关。
  • 新发未治疗肿瘤的皮肌炎患者半乳凝素-9水平高于稳定治疗肿瘤、非肿瘤相关皮肌炎及无皮肌炎肿瘤患者。
  • 半乳凝素-9联合抗TIF1-γ抗体对皮肌炎合并肿瘤预测价值最高(AUC=0.889)。

核心结论

  • 升高的半乳凝素-9水平与肿瘤相关皮肌炎中的肿瘤进展相关,且抗肿瘤治疗后半乳凝素-9下调。
  • 监测血清半乳凝素-9水平和抗TIF1-γ抗体可能是实现肿瘤诊断和预测肿瘤相关皮肌炎结局的有吸引力的策略。

研究设计与样本

  • 通过酶联免疫吸附试验定量检测血清半乳凝素-9,采用Spearman分析评估其与血清学指标的相关性,并利用受试者工作特征(ROC)分析确定半乳凝素-9的截断值。

主要发现

  • 皮肌炎患者血清半乳凝素-9水平为23.38(13.85-32.57)ng/ml,显著高于健康对照的6.81(5.42-7.89)ng/ml(P < 0.0001)。
  • 血清半乳凝素-9水平与CDASI-A评分呈正相关(rs=0.3065,P = 0.0172)。
  • 新发未治疗肿瘤的皮肌炎患者半乳凝素-9水平为31.58(23.85-38.84)ng/ml,高于稳定治疗肿瘤的皮肌炎患者的17.49(10.23-27.91)ng/ml(P = 0.0288)。
  • 新发未治疗肿瘤的皮肌炎患者半乳凝素-9水平高于非肿瘤相关皮肌炎患者的21.05(11.97-28.02)ng/ml(P = 0.0258),也高于无皮肌炎肿瘤患者的7.46(4.90-8.51)ng/ml(P < 0.0001)。
  • 肿瘤相关皮肌炎患者抗肿瘤治疗后血清半乳凝素-9水平显著下降,从27.79(17.04-41.43)ng/ml降至13.88(5.15-20.37)ng/ml(P = 0.002)。

关键数值与推荐

  • 血清半乳凝素-9联合抗TIF1-γ抗体对皮肌炎中肿瘤存在的预测价值最高,AUC=0.889(95% CI 0.803-0.977)。

临床怎么用

  • 原文结论提出监测血清半乳凝素-9水平和抗TIF1-γ抗体可能是实现肿瘤诊断和预测肿瘤相关皮肌炎结局的有吸引力的策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Galectin-9, as immune checkpoint protein, plays a role in regulating autoimmunity and tumour immunity. Therefore, we explored the pathophysiological link between galectin-9 and malignancy in cancer-related DM (CRDM). METHODS: Serum galectin-9 were quantified via enzyme-linked immunosorbent assay, and its association with serological indices was evaluated using Spearman analysis. Receiver operating characteristic (ROC) analysis was utilized to determine the cut-off value of galectin-9. RESULTS: Serum levels of galectin-9 were significantly higher in DM patients [23.38 (13.85-32.57) ng/ml] than those in healthy controls (HCs) [6.81 (5.42-7.89) ng/ml, P < 0.0001], and were positively correlated with the cutaneous dermatomyositis disease area severity index activity (CDASI-A) scores (rs=0.3065, P = 0.0172). DM patients with new-onset and untreated cancer (new-CRDM) [31.58 (23.85-38.84) ng/ml] had higher levels of galectin-9 than those with stable and treated cancer (stable-CRDM) [17.49 (10.23-27.91) ng/ml, P = 0.0288], non-cancer-related DM (non-CRDM) [21.05 (11.97-28.02) ng/ml, P = 0.0258], and tumour patients without DM [7.46 (4.90-8.51) ng/ml, P < 0.0001]. Serum galectin-9 levels significantly decreased [27.79 (17.04-41.43) ng/ml vs 13.88 (5.15-20.37) ng/ml, P = 0.002] after anti-cancer treatment in CRDM patients. The combination of serum galectin-9 and anti-transcriptional intermediary factor 1-γ (anti-TIF1-γ) antibody (AUC = 0.889, 95% CI 0.803-0.977) showed the highest predictive value for the presence of cancer in DM. CONCLUSION: Increased galectin-9 levels were related to tumor progression in CRDM, and galectin-9 was downregulated upon cancer treatment. Monitoring serum galectin-9 levels and anti-TIF1-γ antibodies might be an attractive strategy to achieve tumour diagnosis and predict CRDM outcome.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Shih Y, Chen S, Huang J, et al. Serum level of galectin-9 as a potential biomarker for high risk of malignancy in dermatomyositis. Rheumatology (Oxford). 2024. PMID: 37184873. doi:10.1093/rheumatology/kead222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。